Evidence map›Paper›PMID 42494983›Full record

ArticleMolecular therapy. Advances2026

Optimization of AAV tools to target Müller glial cells for retinal gene therapy.

Daniel Urrutia-Cabrera, Genevieve Huppert, Stephanie W L Chu, Luozixian Wang, Cat Binh Nguy, Chia-Fei Liu, Leszek Lisowski, Chi D Luu, Jiang-Hui Wang, Sandy Hung and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daniel Urrutia-CabreraCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Genevieve HuppertCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Stephanie W L ChuCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Luozixian WangCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Cat Binh NguyCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Chia-Fei LiuCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Leszek LisowskiChildren's Medical Research Institute, The University of Sydney, Sydney, NSW 2145, Australia.
Chi D LuuCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Jiang-Hui WangCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Sandy HungCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Alex W HewittCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Chien-Ling HuangDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.
Tom EdwardsCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Keith R MartinCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.
Raymond C B WongCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reprogramming of Müller glial (MG) cells into retinal neurons has the potential to treat vision loss by regenerating the retina. Development of efficient gene delivery systems to target the MG cells is critical for this approach. Adeno-associated virus (AAV) serotypes and promoter specificity are important factors that influence AAV transduction profile in the retina. However, studies optimizing these parameters to specifically target MG cells are limited, particularly in rats which are widely used for eye research. In this study, we tested 4 AAV serotypes and 13 promoters to optimize gene delivery to human MG cells

Indexed as

AAVcellular reprogrammingMüller gliaretinal gene therapyshort promotersvector design

Identifiers

PMID42494983
PMCPMC13393436

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.